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Human immunodeﬁciency virus (HIV)-associated neurological complications continue to
occur despite the development in antiretroviral treatment. New forms of old opportunistic
infections and increased prevalence of neurocognitive disorders are the challenges that
infectious diseases specialists face in daily clinic. How to screen and treat these disorderseurological complication
AND
ognitive impairment
are subject of debate and new studies are underway to answer these questions. This review
focuses on a brief discussion about opportunistic infections still present in late diagnosed
HIV-infected patients and describes new forms of HIV-related neurological complications.
neurotuberculosis is an important differential diagnosis
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he central nervous system (CNS) is a common site of
nvolvement in HIV patients. The spectrum of neurological
omplications of HIV is very broad, including complications
aused by HIV itself as well as complications due to oppor-
unistic pathogens and neoplasms.1
Following the introduction of highly active antiretroviral
herapy (HAART), the prevalence of opportunistic infections
OIs) decreased in many areas of the world. However, in devel-
ped countries patients continue to present with OIs as the
nitial manifestation of HIV infection because of late diagnosis
f HIV, non-adherence to antiretroviral or prophylactic treat-
ents or unavailability of therapeutic and preventive options.
Moreover, syndromes such as HIV-associated neurocogni-
ive disorder (HAND) have become more prevalent, according
2o some studies. New forms were described, and more
ften infectious diseases specialists face the challenge to
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Este é um artigo Open Access sob a licençainvestigate patients with few, if any, neurological complaints,
even in the presence of suppressed viral load.
This review focuses on recent developments in the ﬁeld of
neurological complications of HIV in the HAART era, and will
discuss old OIs and the new forms of HIV-related neurological
complications.
The “old OIs”
The most common intra-cranial lesions in acquired immun-
odeﬁciency syndrome (AIDS) patients are toxoplasma
encephalitis (TE), cryptococcal meningitis with mucinous
pseudocysts formation (CM), primary central nervous system
lymphoma (PCNSL), and progressive multifocal leukoen-
cephalopathy (PML).3 In developing countries such as Brazil,argador Vieira Cavalcanti, 1089, Curitiba, Paraná, 80810050, Brazil.
for TE, being the second most common HIV intracranial
complication.4 Table 1 shows the main MRI patterns of the
 de CC BY-NC-ND
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Table 1 – Common image patterns in MRI related to neurological complications of HIV and main etiologies.
Image pattern Probable diagnosis
Focal lesion in brain Mass effect with post Gd enhancement
Focal lesion and no enhancement
No mass affect nor enhancement
No mass effect but with enhancement
TE
PCNSL
TB
Histoplasmosis
Criptococcosis
PML
Viral encephalitis (HSV, CMV, VZV)
CNS arteritis
Diffuse disease in encephalic
parenchima
Atrophy and hiperintensities in white matter, no
mass effect and no enhancement
HIV-associated encephalopathy
Meningitis Meningeal enhancement Primary meningitis related to HIV-1
Methastatic lymphoma
Other viral meningitis
Ventriculitis Periventricular enhancement Necrotizing ventriculitis caused by CMV
em l
, varTE, toxoplasma encephalitis; PCNSL, primary central nervous syst
cephalopathy; HSV, herpes simplex virus; CMV, cytomegalovirus; VZV
most common etiologies of CNS involvement in HIV-infected
patients.
TE is the most common cause of CNS mass lesions in
patients infected with HIV. The seroprevalence of toxoplasma
varies from 10% to 40% in the United States to 70% to 90%
in Europe. Toxoplasma gondii (TG) is a protozoan which can
also cause disease in immunocompetent patients, but in this
setting, the disease is usually benign and does not affect the
CNS.5,6
Usually, the CD4 cell count of patients with HIV presenting
with TE is less than 100, but some patients can develop the
disease with CD4 cell counts between 100 and 200 cells/mm3.7
The prevalence of TE has decreased with the use of trimetho-
prim sulfamethoxazole for prophylaxis against Pneumocystis
jirovecii.8 Table 2 shows the diagnosis and treatment charac-
teristics of CNS OIs.
Clinical characteristics of TE are nonspeciﬁc and depend
on where the lesion is located in the brain.6 Most commonly,
lesions from TE are located in the basal ganglia or subcortical
white matter, although any part of the CNS can be involved.
Concomitant diffuse atrophy disproportionate to the patient’s
age is very common, present in more than 1/3 of patients. TE
lesions are usually abscesses of more than 3 cm in diameter
that most commonly show enhancement after contrast injec-
tion. On brain CT, lesions are hypodense and surrounded by
edema and enhance with contrast, classically presenting “ring
enhancement” or “asymmetric target sign”. MRI can often
reveal multiple lesions in a patient presenting with a single
lesion on CT.5
The diagnosis of TE is based on clinical and laboratory ﬁnd-
ings. A high degree of suspicion is warranted for a patient with
HIV infection, CD4 less than 100 cells/mm3, positive serum
anti-toxoplasma IgG (which demonstrates previous contact
with the protozoan), and focal signs on neurological exam.
Brain CT or MRI should be performed with pre- and post-
contrast images, but in many resource-limited settings these
may not be available. If the diagnosis is suspected, an empiric
treatment with sulphadiazine, pyrimetamine, and folinic acid
should be instituted.6
Usually, TE shows a rapid response to therapy as shown
by image resolution or clinical improvement. Treatment isymphoma; TB, tuberculosis; PML, progressive multifocal leukoen-
icella-zoster virus; CNS, central nervous system.
considered a failure if no clinical and radiographic improve-
ments are observed after two weeks of therapy. In such
cases, a brain biopsy is indicated to search for an alternative
diagnosis.6
The principal differential diagnosis of TE in some countries
is PCNSL.9 This is a neoplasm linked to infection with Epstein-
Barr virus (EBV) and occurs in advanced HIV disease (CD4 less
than 100 cells/mm3). It causes mass lesions with multiple
patterns of contrast enhancement on radiographic imaging,
very similar to TE. Diagnosis can be made by CSF analysis
with presence of neoplastic cells on ﬂow cytometry, associ-
ated with a positive EBV DNA by polymerase chain reaction
(PCR). Chemotherapy and radiotherapy are the treatment.3
Leptomeningitis is very common in the clinical picture
of CNS TB. Also, CNS TB can cause infarction, abscess for-
mation, and granuloma.10 Usually, the lesions present with
mass-effect and IV contrast enhancement on CT and MRI.11
CSF tests can help to make the diagnosis, with a mononu-
clear pleocytosis, low glucose, and increased protein levels.
CSF must be sent for M. tuberculosis culture, but this can take
weeks to produce a result. M. tuberculosis DNA by PCR in CSF
may lead to a faster diagnosis, but the sensitivity is variable.
Additionally, a search for extra-neural sites of tuberculosis can
be helpful. Around 20% of patients will present with extra-
neural signs of active tuberculosis, such as lung lesions, that
are more easily accessible for collection of material to conﬁrm
the diagnosis.10
Cryptococcus neoformans, besides being a very common
cause of meningitis, can also cause gelatinous pseudocyst
formation, with the deposit of a thick material in the perivas-
cular spaces of periventricular white-matter (Virchow-Robin
spaces). Usually, these do not enhance after IV contrast
injection, and they cause no mass effect. Although not
pathognomonic, their appearance is highly suggestive of
cryptococcosis.12
Neurocysticercosis is among the most prevalent CNS infec-
tions in many developing countries. It is diagnosed when a
patient in endemic areas shows a radiographic image compat-
ible with the disease (i.e. a cystic lesion with different patterns
of enhancement after IV contrast) and has a positive CSF sero-
logic reaction (immunoblot).13
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Table 2 – Intra-cranial diseases, their etiologic agents, useful tests for diagnosis and treatment options.
Disease Agent Diagnostic tests Primary treatment Supressive treatment
Toxoplasmosis Toxoplasma gondii MRI showing a mass-effect
lesion located in basal ganglia
or cortex, with ring or
asymmetrical-target
enhancement, Positive
anti-toxoplasman serum and
CSF IgG, CSF Toxoplasma gondii
DNA by PCR
Sulfadiazine 1-1.5 g
q6h+pyrimethamine 200mg
ﬁrst day followed by
pyrimethamine
50-75mg/day+ folinic acid
10-20 mg/day
Sulphadiazine
500-1000mg
q6h+pyrimethamine
25-50 mg/day+ folinic
acid 10-20mg/day
Central nervous system
lymphoma
Related to EBV MRI showing a mass-effect
lesion in periventricular
white-matter, with ring or
nodular contrast
enhancement, positive CSF
EBV DNA by PCR
Chemotherapy / radiotherapy
(role of gancyclovir?)
N/A
Tuberculoma or
tuberculous abscess
Mycobacterium
tuberculosis
MRI showing mass-effect
lesion with multiple patterns
of contrast enhancement,
positive CSF M. tuberculosis
culture, positive CSF M.
tuberculosis DNA by PCR
Treat according to local
guidelines, local data on
resistance and patientıˇs history
of pre-exposure to anti-TB
treatment
RFP 600 mg/day+ INH 5
mg/Kg/day+PZD 25-30
mg/Kg/day (+- etambutol 15-25
mg/Kg/day) +B6 vitamin*
N/A
Cryptococcal
meningoencephalitis
Cryptococcus sp. MRI showing gelatinous
pseudocysts located in basal
ganglia, thamalus or
periventricular areas,
non-enhancing and no
signiﬁcant mass-effect
IV ﬂuconazol 400-800 mg/day
or IV amphotericin B 0.7
mg/Kg/day
Oral Fluconazol 200
mg/day
PML JC virus MRI demonstrating white
matter changes, no mass effect
and no contrast enhancement
(in case of classical PML),
positive CSF DNA JC virus
HAART N/A
Cysticercosis Cysticercus (larval
cysts of pork
tapeworm Taenia
solium)
MRI showing cystic lesion
(concomitant calciﬁed lesions
can suggest diagnosis),
serological tests: serum and
CSF (immunoblot)
Depending on location of
lesions and stage,
dexamethasone+ - albendazol
N/A
MRI,magnetic resonance imaging; CSF, cerebrospinal ﬂuid; PCR, polymerase chain reaction; EBV, Epstein-Barr virus; N/A, not available; TB, tuber-
culosis; RFP, rifampin; INH, isoniazid; PZD, pyrazinamide; PML, progressive multifocal leukoencephalopathy; HAART, highly active antiretroviral
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∗ B6 vitamin is used to antagonized neurotoxic effects of INH.
The prevalence of neurocysticercosis is not higher among
IV-infected individuals.14 However, some atypical cases have
een described, mostly in resource-limited settings. Treat-
ent should be started with corticosteroids and/or cysticidal
herapy (praziquantel or albendazol), according to the stage
nd topography of the disease in the CNS.
hat is new with the old CNS OIs?
rogressive multifocal leukoencephalopathy (PML) is a disease
aused by the polyomavirus JC virus (JCV), and is associated
ith severe immunosupression (CD4 less than 100 cells/mm3),
lthough some cases with a higher CD4 count have been
escribed. The main feature is a progressive lesion of white
atter causing variable neurologic signs and symptoms, no
ever, and a progressive disease. Diagnosis is suggested by thetypical appearance in MRI complemented by a positive CSF
JCV DNA by nested PCR. There is no speciﬁc treatment, but
improvement or at least stability has been reported in some
patients due to HAART.15
Koralnik et al. described an HIV-infected patient with JCV
infection restricted to granule cell neurons of the cerebellum
and with compatible symptoms. That was a description of a
new syndrome called JCV granule cell neuronopathy. Patients
with this new variant have no typical white matter changes
on MRI but present with cerebellar atrophy.16
Another variant of the “classical” PML is the “inﬂamma-
tory” PML. Patients with previous diagnosis of PML who start
HAART develop worsening of previous known PML.17 In some
cases, patients have undiscovered subclinical PML during
HAART.18 In both cases, image tests are different from clas-
sical PML because in inﬂammatory PML, an MRI can show
mass effect and enhancement. This entity was reported to be
376 braz j infect d i s . 20
ANI
MCMD
HAD
Fig. 1 – Clinical stages of cognitive impairment in
HIV-infected patients. ANI, asymptomatic neurocognitive
impairment; MCMD, minor cognitive motor disorder; HAD,
dementia. MRI may show diffuse white-matter hyperintensi-HIV-associated dementia.
associatedwith fatal cases of PML. Steroidsmayhelp to reduce
the exacerbated inﬂammatory response and contribute to bet-
ter outcomes.
HIV-associated neurocognitive disorder
HIV-associated neurocognitive disorder (HAND) is the new
deﬁnition for what used to be called AIDS-dementia complex
– the phenotypic form of HIV encephalitis. In the 1993 Centers
for Disease Control and Prevention (CDC) classiﬁcation, HAND
was deﬁned as an AIDS-deﬁning illness.
HAND is the most common cause of dementia in young
people, and one of the few treatable dementias. It usually has
an insidious onset and a chronic, progressive course, bring-
ing disability to many HIV patients. Also, this syndrome may
cause poor adherence to HIV care, job loss, decline of driv-
ing ability, and lesser adherence with HIV medications, with
increased morbidity and mortality.
In 2007, new criteria were published deﬁning how to
diagnoseHAND, including awide spectrumofHIV-related cog-
nitive impairments19 (Table 3, Fig. 1) as follows:
• Asymptomatic neurocognitive impairment (ANI)
• Mild cognitive motor disorder (MCMD)
• HIV-associated dementia (HAD).
In the HAART era, the incidence of HAND has decreased,
but the prevalence has paradoxically increased, with mild
forms of the disease observed more commonly than before.
In developing countries, patients often died before the diag-
nosis of HAND could be made. However, with the broad use of
HAART, this scenario is changing.
Table 3 – HAND deﬁnitions.
Syndromes19
Asymptomatic neurocognitive
impairment
Patient has no complai
and one or more stand
Mild cognitive motor disorder Same as ANI but patien
HIV-associated dementia Signiﬁcant impairment
neuropsychological sym
matched controls
ANI, asymptomatic neurocognitive impairment.
∗ Excluding other causes of neuropsychological symptoms.12;16(4):373–378
Although HAND is observed more frequently in patients
with severe immunosupression (usually a CD4 count less than
100 cells/mm3), it can occur in patients with higher CD4 cell
counts, especially in its subtle forms. CD4 nadir less than 50
cels/mm3 is a risk factor for development of neurocognitive
disorder in HIV patients.20
HAND is characterized by the triad of cognitive impair-
ment, behavioral abnormality, and motor dysfunction. Clas-
sically, HIV dementia is considered a subcortical dementia,
characterized by more motor symptoms and less memory
and language impairment than is commonly seen in cortical
dementias such as Alzheimer’s disease.21 Recently, asymp-
tomatic and mild forms of neurocognitive impairment were
shown to actually increase the risk for future symptomatic
decline. This may be a reason why infectious diseases special-
ists should actively screen HIV patients with no neurological
or cognitive complains in daily practice.22
The clinical diagnosis of HAND is ideally based on the
patient’s performance on neurocognitive tests, as described.
Unfortunately these tests need to be applied by specially
trained professionals (such as psychologists or neurologists),
and in many resource-limited countries they are not widely
available. Another way to screen patients for neurocognitive
impairment is through the use of scales, such as the HIV
Dementia Scale or the International HIV Dementia Scale. The
latter is a bedside test that has been developed and applied
in populations from the United States and Uganda, show-
ing high speciﬁcity and sensitivity. This scale was also useful
whenapplied toHIV-infectedpatients from India. This test can
be administered by non-neurologists, and is a useful tool for
detection of cognitive impairment. If a patient screens positive
by this scale, he/she can be referred for further neurocognitive
evaluation with additional neuropsychological testing.23
CSF ﬁndings in HAND patients are non-speciﬁc, usu-
ally showing normal or mild pleocytosis, normal or mildy
increased protein and normal glucose. It is important to
exclude opportunistic infections. CSF HIV-1 viral load is not
reliable in the diagnosis of cognitive disorder caused by HIV
infection itself but, when positive, it may suggest a CSF HIV
escape and may guide therapy to a regimen with improved
CSF penetration, according to penetration score.24
Cranial CT and MRI may show cortical atrophy, but the
degree of atrophy has not been correlated with the grade ofties in the deep white matter with atrophy of bilateral caudate
nucleus, but these results are non-speciﬁc. Care should be
taken with the use of imaging studies, because patients with
Deﬁnition
nts (asymptomatic). Impairment in two or more neuropsychological
ard deviation below the mean for matched controls*
ts have mild complaints
(loss of activities of daily living) and impairment in two or more
ptoms and two or more standards deviation below the mean for
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Table 4 – CNS penetration score.
Drug CNS, penetration score
4 3 2 1
NRTI Zidovudine Abacavir Lamivudine
Emtricitabine Stavudine Tenofovir
Didanosine Zalcitabine
NNRTI Nevirapine Efavirenz Etravirine
Delavirdine
PI Indinavir/r Darunavir/r Atazanavir Nelﬁnavir
Fosamprenavir/r Atazanavir/r Ritonavir
Lopinavir/r Fosamprenavir Saquinavir/r
Indinavir Saquinavir
Tipranavir/r
CCR5 inhibitor Maraviroc
Fusion inhibitor Enfuvirtide
Integrase inhibitor Raltegravir
inhib
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rCNS, central nervous system; NRTI, nucleoside reverse transcriptase
AND may have a normal MRI and patients with bilateral
hite matter hyperintensities may have an alternative diag-
osis. Image studies must rule out alternative diagnosis.
There is no speciﬁc treatment for HAND. Antiretroviral
rugs that penetrate the blood brain barrier (BBB) are cur-
ently considered the best choices for treatment of these
atients.25,26
enetration of ARV through the BBB: the CPE
core
any drugs were investigated in the treatment of HAND with
o good results so far. At this moment, the best treatment for
AND is ARV with good CNS penetration. In order to evalu-
te general characteristics of available ARV to penetrate the
NS, Letendre et al. developed a CNS penetration score (CPE)
Table 4), which showed that higher scores were related to
ower CSF viral load.25,26
Other studies presented discordant results when ana-
yzing neuro-HAART (HAART constituted by drugs with
mproved BBB penetration) ability to improve neurocognitive
mpairment, with one study showing worsening of cognitive
erformance in patients with higher CPE scores.27 This result
uestioned neural toxicity but, overall, more randomized clin-
cal trials are needed to better answer the question of whether
euro-HAART can really improve cognitive performance in
AND patients.
At this moment, starting neuro-HAART in patients with
o cognitive impairment is not indicated, but some guide-
ines already suggest changing the ARV regimen in patients
iagnosed with HAND in order to improve their cognitive
erformance.28
In conclusion, neurological involvement in HIV-infected
atients is still important, even in the post-HAART era, with
ot only new forms or atypical presentations of old OIs, but
lso milder forms of neurocognitive impairment. New clini-
al trials investigating easier diagnostic tools for patients with
ognitive impairment, the utility of neuro-HAART, and clini-
al evaluation of those patients are ongoing to answer many
oubts the scientiﬁc community still has.
1itor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
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